Literature DB >> 12509766

Validating survivin as a cancer therapeutic target.

Dario C Altieri1.   

Abstract

Acquisition of the ability to evade cellular suicide, or apoptosis, is one of the master switches that contributes to cellular transformation and, ultimately, to invasive cancer. Much has been learned about the molecular organization of apoptotic pathways and their regulators, but the identification and validation of translational targets for apoptosis-based cancer therapy has posed a great challenge. Survivin is an attractive candidate for cancer therapy, so what is its potential applicability in the clinic?

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12509766     DOI: 10.1038/nrc968

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  379 in total

1.  Combined in silico and experimental approach for drug design: the binding mode of peptidic and non-peptidic inhibitors to hsp90 N-terminal domain.

Authors:  Simona Tomaselli; Massimiliano Meli; Janet Plescia; Lucia Zetta; Dario C Altieri; Giorgio Colombo; Laura Ragona
Journal:  Chem Biol Drug Des       Date:  2010-11       Impact factor: 2.817

2.  Epstein-Barr Virus nuclear antigen 1 (EBNA1) confers resistance to apoptosis in EBV-positive B-lymphoma cells through up-regulation of survivin.

Authors:  Jie Lu; Masanao Murakami; Subhash C Verma; Qiliang Cai; Sabyasachi Haldar; Rajeev Kaul; Mariusz A Wasik; Jaap Middeldorp; Erle S Robertson
Journal:  Virology       Date:  2010-11-19       Impact factor: 3.616

3.  Immunoexpression of Survivin in non-neoplastic lymphoid tissues and malignant lymphomas using a new monoclonal antibody reactive on paraffin sections.

Authors:  José Vassallo; Talal Al Saati; Randy D Gascoyne; Kathyrn Welsh; John C Reed; Pierre Brousset; Georges Delsol
Journal:  J Hematop       Date:  2010-01-30       Impact factor: 0.196

4.  Expression of Survivin in pancreatic cancer and its correlation to expression of Bcl-2.

Authors:  Jian-Guo Qiao; Yu-Qing Zhang; Yu-Chun Yin; Zui Tan
Journal:  World J Gastroenterol       Date:  2004-09-15       Impact factor: 5.742

5.  Cell division and cell survival in the absence of survivin.

Authors:  Dun Yang; Alana Welm; J Michael Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-11       Impact factor: 11.205

Review 6.  Survivin and leukemia.

Authors:  Xiu Li Cong; Zhong Chao Han
Journal:  Int J Hematol       Date:  2004-10       Impact factor: 2.490

7.  Targeting energetic metabolism: a new frontier in the pathogenesis and treatment of pulmonary hypertension.

Authors:  Rubin M Tuder; Laura A Davis; Brian B Graham
Journal:  Am J Respir Crit Care Med       Date:  2011-11-10       Impact factor: 21.405

8.  Expression level of wild-type survivin in gastric cancer is an independent predictor of survival.

Authors:  Hua Meng; Cai-De Lu; Yu-Lei Sun; De-Jian Dai; Sang-Wong Lee; Nobuhiko Tanigawa
Journal:  World J Gastroenterol       Date:  2004-11-15       Impact factor: 5.742

9.  Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis.

Authors:  Takehiko Dohi; Elena Beltrami; Nathan R Wall; Janet Plescia; Dario C Altieri
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

Review 10.  Survivin as a novel target protein for reducing the proliferation of cancer cells.

Authors:  Dongyu Li; Chenghao Hu; Huibin Li
Journal:  Biomed Rep       Date:  2018-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.